CASTLE BIOSCIENCES, INC. Proceeds from Long-term Lines of Credit
CASTLE BIOSCIENCES, INC. (CSTL) reported Proceeds from Long-term Lines of Credit of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2020-03-10
- CASTLE BIOSCIENCES, INC. proceeds from long-term lines of credit for the quarter ending 2019-12-31 was $0.00.
- CASTLE BIOSCIENCES, INC. proceeds from long-term lines of credit for the quarter ending 2019-09-30 was $0.00.
- CASTLE BIOSCIENCES, INC. proceeds from long-term lines of credit for the quarter ending 2018-12-31 was $0.00.
- CASTLE BIOSCIENCES, INC. proceeds from long-term lines of credit for the quarter ending 2018-09-30 was $0.00.
- CASTLE BIOSCIENCES, INC. proceeds from long-term lines of credit for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- CASTLE BIOSCIENCES, INC. proceeds from long-term lines of credit for fiscal 2018 was $1.00M.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $0.00 derived: sum of 2 quarters · filed 2020-03-10 | $0.00 10-K · filed 2020-03-10 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2019-09-03 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $0.00 derived: sum of 2 quarters · filed 2020-03-10 | $1.00M 10-K · filed 2020-03-10 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.00M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $1.00M 10-Q · filed 2019-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |